Two healthcare stocks poised for long-term growth are Johnson & Johnson (JNJ) and Vertex Pharmaceuticals (VRTX), according to a recent analysis. Johnson & Johnson’s enduring market presence, innovative pipeline, and strong balance sheet position it well to navigate challenges over the next two decades. The company benefits from a wide moat, including patent protections and significant pricing power, alongside a history of consistent dividend increases, solidifying its status as a reliable investment.
Vertex Pharmaceuticals, on the other hand, has established a monopoly in the cystic fibrosis treatment market, allowing it to leverage significant pricing power. Its products remain critical for patients, ensuring a steady revenue stream until patent expirations in the late 2030s. Vertex is also actively developing new treatments for other conditions, indicating potential for sustained growth beyond its current market.
Investors seeking stability and long-term returns may find these stocks attractive, given their strong fundamentals and strategic positioning in the evolving healthcare landscape.
Source: fool.com